SS&C Technologies Holdings, Inc. (NASDAQ:SSNC) Q4 2025 Earnings Call Transcript February 5, 2026 SS&C Technologies Holdings, Inc. beats earnings expectations. Reported EPS is $1.69, expectations were ...

Weak characters kill loftier ambitions, but a brisk pace keeps the combat lively. PC Gamer's got your back Our experienced team dedicates many hours to every review, to really get to the heart of what ...

GameSpot may get a commission from retail offers. Code Vein 2's greatest strength is the variety of options it gives you in creating your personal vampiric warrior. Will you drain the blood from your ...

Dominik Bošnjak is a freelance writer from Croatia. He has been writing about games for as long as he can remember and began doing so professionally in 2010 because an opportunity presented itself ...

In this fast-paced digital world, DevOps teams are operating in complex, high-velocity enterprise environments. Distributed development teams, microservices architectures, and always-on CI/CD ...

For over 5 years, Arthur has been professionally covering video games, writing guides and walkthroughs. His passion for video games began at age 10 in 2010 when he first played Gothic, an immersive ...

If one would claim that the role of art is to create something wholly original, then Code Vein 2 stands in direct opposition to this. The opening minutes feel like the cutscene equivalent of a friend ...

Seven years after the original, Bandai Namco release a surprise sequel to Code Vein that combines familiar Soulslike gameplay with time-travelling vampires. Back when the original Code Vein was ...

Stearns and Poletti present a technically impressive study that aims to uncover a deeper understanding of microsaccade function: their role in perceptual modulation and the associated temporal ...

Code Vein II starts off with a fairly standard story trope that requires the player, as the silent protagonist, to travel to the past to save the future. The present is currently doomed by the Luna ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2025 Earnings Call Transcript February 17, 2026 Halozyme Therapeutics, Inc.